Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III BMS-986213 plus chemotherapy versus nivolumab or placebo plus chemotherapy in first-line LAG-3-positive gastric or gastroesophageal junction adenocarcinoma
NL-OMON46592Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab + relatlimab, nivolumab and relatlimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival and Progression-free survival. Planned start Aug 2018; status: withdrawn.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON46592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46592.